APLM — APOLLOMICS INC. CLASS A ORDINARY SHARES (Healthcare >> Biotechnology)
APLM FAQ
What is APLM's P/E ratio?
APOLLOMICS INC. CLASS A ORDINARY SHARES (APLM) currently trades at a P/E ratio of 19.14.
What is APLM's ROE?
APOLLOMICS INC. CLASS A ORDINARY SHARES reports a Return on Equity (ROE) of 1,220.73%.
What is APLM's dividend yield?
APOLLOMICS INC. CLASS A ORDINARY SHARES offers a dividend yield of 0.00%.
What is APLM's Deepscope Quality Score?
Deepscope rates APLM's overall financial quality at 54 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy APLM?
Deepscope's AI Timing Score for APLM is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does APLM belong to?
APOLLOMICS INC. CLASS A ORDINARY SHARES is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 14.00
Price
0.00
(0.00%)
Day Change
|
|
|---|
APLM, the overall quality is not quite good ( Quality = 54) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROA is too relatively low compare to ROE
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 14.00 |
| PBV / Sector |
-9.59 / 4.63
|
| Earning Per Share | -17.82 |
| PE / Sector |
19.14 / 17.43
|
| PEG or PE/Growth / Sector |
-0.32 / 0.53
|
| Average 1M Daily Value |
0.13 M
GREAT
|
| Average 1W Daily Value |
0.12 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
56% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:26 |
| Symbol | APLM |
| Name | APOLLOMICS INC. CLASS A ORDINARY SHARES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 2.20 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 30.57 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 989 East Hillsdale Blvd., Foster City, CA, United States, 94404
Phone: 650 209 4055
Website: https://www.apollomicsinc.com
Sector: Healthcare >> Biotechnology
Description: Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google